I am not optimistic about remlifanserin’s phase 3 success, with a probability of success to 25% due to efficacy and trial ...

Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell 6% after the company reported results from its Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, with the trial missing its ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with ...

That morning, the HR director reported to the management team with a smile: "The leadership training has been effective. Participant engagement scores have risen significantly. The p-value is 0.03." A ...

The vitamin D supplement you take every day. It was recommended by your doctor because it is 'scientifically backed.' The study that served as the basis: a large-scale randomized controlled trial of ...

CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo.

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.

While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body ...

A new study confirms that EBV infection increases thew risk of MS and shows that common herpesviruses have differing roles in the disease.

Researchers found that genome-wide plasma cfDNA methylation profiles collected before diagnosis contained early molecular ...

What you are not permitted to do under the federal securities laws is take that negative data, rewrite the grading rubric twenty-four hours before unblinding the results, tell the public you have ...